Loading...
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose, J Falk, S Finch-Jones, M O'Reilly, D Siriwardena, A Hornbuckle, J Peterson, M Rees, M Iveson, T
Primrose, J
Falk, S
Finch-Jones, M
O'Reilly, D
Siriwardena, A
Hornbuckle, J
Peterson, M
Rees, M
Iveson, T
Citations
Altmetric:
Abstract
Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to these chemotherapy regimens results in an overall survival advantage in patients with advanced disease who have the KRAS exon 2 wild-type tumour genotype. We aimed to assess the benefit of addition of cetuximab to standard chemotherapy in patients with resectable colorectal liver metastasis.
Description
Date
2014-04-04
Publisher
Collections
Keywords
Type
Article
Citation
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. 2014: Lancet Oncol